Grifols (Grifols) Earnings per Share (Diluted)

: $0.28 (TTM As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

Grifols's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $0.09. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.28.

Grifols's EPS (Basic) for the three months ended in Sep. 2023 was $0.09. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.28.

Grifols's EPS without NRI for the three months ended in Sep. 2023 was $0.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $0.18.

During the past 12 months, Grifols's average EPS without NRIGrowth Rate was -52.40% per year. During the past 3 years, the average EPS without NRIGrowth Rate was -45.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was -32.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was -11.50% per year.

During the past 13 years, Grifols's highest 3-Year average EPS without NRI Growth Rate was 86.80% per year. The lowest was -45.00% per year. And the median was 6.00% per year.

Grifols Earnings per Share (Diluted) Historical Data

The historical data trend for Grifols's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Earnings per Share (Diluted)

1.01

1.10

0.32

0.33

0.10

Grifols Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Earnings per Share (Diluted)																0.07	0.03	0.10	0.09	0.09

Competitive Comparison

For the Drug Manufacturers - General subindustry, Grifols's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Grifols PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Grifols's PE Ratio distribution charts can be found below:

* The bar in red indicates where Grifols's PE Ratio falls into.

Grifols Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Grifols's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(64.684	-	0)	/	679.756
	=	0.10

Grifols's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2023 is calculated as

Diluted Earnings Per Share (Q: Sep. 2023 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(63.546	-	0)	/	679.092
	=	0.09

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.28

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Grifols (NAS:GRFS) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Grifols Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Grifols's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols (Grifols) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFP:Mexico GRFe:UK GRFPe:UK 0RDV:UK 0RDU:UK GRF.P:Spain GRF:Spain G0F0:Germany G0F:Germany G0FB:Germany OZTA:Germany OZTA:Germany G0FB:Germany

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.